These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 20118966)

  • 21. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis.
    Sarkisian CJ; Keister BA; Stairs DB; Boxer RB; Moody SE; Chodosh LA
    Nat Cell Biol; 2007 May; 9(5):493-505. PubMed ID: 17450133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Redox-inactive analogue of tocotrienol as a potential anti-cancer agent.
    Yano T; Sato A; Sekine M; Virgona N; Ota M
    Anticancer Agents Med Chem; 2013 Mar; 13(3):496-501. PubMed ID: 22721395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TATA box-binding protein-associated factor 12 is important for RAS-induced transformation properties of colorectal cancer cells.
    Voulgari A; Voskou S; Tora L; Davidson I; Sasazuki T; Shirasawa S; Pintzas A
    Mol Cancer Res; 2008 Jun; 6(6):1071-83. PubMed ID: 18567809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer: The Ras renaissance.
    Ledford H
    Nature; 2015 Apr; 520(7547):278-80. PubMed ID: 25877186
    [No Abstract]   [Full Text] [Related]  

  • 25. Proteomics analysis reveals insight into the mechanism of H-Ras-mediated transformation.
    Jin BF; He K; Wang HX; Bai B; Zhou T; Li HY; Man JH; Liu BY; Gong WL; Wang J; Li AL; Zhang XM
    J Proteome Res; 2006 Oct; 5(10):2815-23. PubMed ID: 17022653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Apoptosis and non-apoptotic deaths in cancer development and treatment response.
    de Bruin EC; Medema JP
    Cancer Treat Rev; 2008 Dec; 34(8):737-49. PubMed ID: 18722718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
    He H; Hirokawa Y; Levitzki A; Maruta H
    Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNAs: small but potent oncogenes or tumor suppressors.
    Lee YS; Dutta A
    Curr Opin Investig Drugs; 2006 Jun; 7(6):560-4. PubMed ID: 16784027
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras.
    Pantoja C; Serrano M
    Oncogene; 1999 Sep; 18(35):4974-82. PubMed ID: 10490832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel Ras pathway inhibitor induces apoptosis and growth inhibition of K-ras-mutated cancer cells in vitro and in vivo.
    Jasinski P; Zwolak P; Terai K; Dudek AZ
    Transl Res; 2008 Nov; 152(5):203-12. PubMed ID: 19010291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of sugar-derived Ras inhibitors.
    Peri F; Airoldi C; Colombo S; Martegani E; van Neuren AS; Stein M; Marinzi C; Nicotra F
    Chembiochem; 2005 Oct; 6(10):1839-48. PubMed ID: 16196015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant transformation of an infinite life span human fibroblast cell strain by transfection with v-Ki-ras.
    Fry DG; Milam LD; Dillberger JE; Maher VM; McCormick JJ
    Oncogene; 1990 Sep; 5(9):1415-8. PubMed ID: 2216465
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate.
    Trachootham D; Zhou Y; Zhang H; Demizu Y; Chen Z; Pelicano H; Chiao PJ; Achanta G; Arlinghaus RB; Liu J; Huang P
    Cancer Cell; 2006 Sep; 10(3):241-52. PubMed ID: 16959615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tel induces a G1 arrest and suppresses Ras-induced transformation.
    Rompaey LV; Potter M; Adams C; Grosveld G
    Oncogene; 2000 Nov; 19(46):5244-50. PubMed ID: 11077441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
    Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
    Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Valine substitution].
    Lalaiants IE; Milovanova LS
    Biofizika; 1990; 35(2):231-5. PubMed ID: 2196088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor.
    Shalom-Feuerstein R; Lindenboim L; Stein R; Cox AD; Kloog Y
    Cell Death Differ; 2004 Feb; 11(2):244-7. PubMed ID: 14576773
    [No Abstract]   [Full Text] [Related]  

  • 39. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.
    Youn CK; Kim MH; Cho HJ; Kim HB; Chang IY; Chung MH; You HJ
    Cancer Res; 2004 Jul; 64(14):4849-57. PubMed ID: 15256455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects.
    Marcus K; Mattos C
    Clin Cancer Res; 2015 Apr; 21(8):1810-8. PubMed ID: 25878362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.